Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CIBC Private Wealth Group LLC

CIBC Private Wealth Group LLC lessened its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 99.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,053 shares of the biopharmaceutical company's stock after selling 963,451 shares during the period. CIBC Private Wealth Group LLC's holdings in Halozyme Therapeutics were worth $146,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Heck Capital Advisors LLC acquired a new stake in Halozyme Therapeutics during the fourth quarter worth $29,000. CBIZ Investment Advisory Services LLC acquired a new position in Halozyme Therapeutics during the 4th quarter worth approximately $29,000. Smartleaf Asset Management LLC grew its stake in shares of Halozyme Therapeutics by 29.2% during the fourth quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares in the last quarter. Venturi Wealth Management LLC purchased a new position in Halozyme Therapeutics in the fourth quarter valued at $69,000. Finally, Parkside Financial Bank & Trust raised its stake in Halozyme Therapeutics by 21.8% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the sale, the director now directly owns 38,611 shares in the company, valued at $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,200 shares of company stock worth $1,286,568. 2.40% of the stock is owned by company insiders.

Remove Ads

Analysts Set New Price Targets

HALO has been the topic of several recent analyst reports. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Wells Fargo & Company cut their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Benchmark restated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Piper Sandler raised their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a report on Friday, January 10th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $62.78.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO traded up $2.52 during mid-day trading on Friday, hitting $60.22. 1,839,648 shares of the company were exchanged, compared to its average volume of 1,409,402. Halozyme Therapeutics, Inc. has a 1-year low of $37.73 and a 1-year high of $66.00. The firm has a market cap of $7.44 billion, a price-to-earnings ratio of 17.56, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. The stock has a 50 day simple moving average of $60.22 and a 200-day simple moving average of $54.93.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.